Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells.

Breckpot K, Heirman C, Neyns B, Thielemans K.
J Gene Med. 2004 Nov;6(11):1175-88.

Dendritic cells (DCs) are pivotal regulators of immune reactivity and immune tolerance. The observation that DCs can recruit naive T cells has invigorated cancer immunology and led to the proposal of DCs as the basis for vaccines designed for the treatment of cancer. Designing effective strategies to load DCs with antigens is a challenging field of research. The successful realization of gene transfer to DCs will be highly dependent on the employed vector system. Here, we review various viral and non-viral gene transfer systems, and discuss their distinct characteristics and possible advantages and disadvantages in respect to their use in DC-based immunotherapy.

URL: http://www3.interscience.wiley.com/journal/109667923/abstract?CRETRY=1&SRETRY=0

Pub Med: http://www.ncbi.nlm.nih.gov/pubmed/15468193

created over 15 years ago (13 January 2010)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]